Where output becomes side effect
Pre-action enforcement at non-bypassable control points for agent execution, tool use, and downstream action.
Meridian Verity products are narrow entry points into one fail-closed control architecture. Choose runtime action, conformance, or clinical reliance. Prove PASS / HOLD / FAIL behavior offline. Expand only after fit is real.
Shared posture Local verification · Replayable receipts · Deterministic outcomes · Procurement-ready review
These are not disconnected products. They are focused entry surfaces into the same control posture: verify, permit, gate, and record evidence before consequential effect.
Pre-action enforcement at non-bypassable control points for agent execution, tool use, and downstream action.
Conformance packs, replayable receipts, and procurement-readable PASS / FAIL / HOLD behavior for serious evaluation paths.
A clinical and revenue-cycle entry point where proof, continuity, and admissible automation matter more than presentation copy.
The right move is not to pitch the whole stack. It is to start at the boundary the buyer already owns.
Use the runtime-action lane when delegated execution, tool use, network egress, or downstream actuation are the real boundary.
Use conformance packs when the first question is not product messaging but what another party can verify and accept.
Use CTC when care delivery, payment consequence, or regulated operational reliance is the boundary that must be proven.
Keep the first conversation narrow, verifiable, and operationally legible.
Pick the boundary that already controls real side effects or real reliance.
Define reason codes, expected behavior, and what PASS / HOLD / FAIL really means.
Prove the evidence path and deterministic behavior before broader integration discussions.
Widen scope after the boundary, evidence, and buyer path have all actually landed.
Each route should feel inevitable: verify, inspect, procure, then go deeper only where needed.
Start with local verification and the trust surfaces that outrank page copy.
Bring the conversation into acceptance criteria, conformance, and procurement-ready packets.
When the runtime-control story matters, the patents page shows the issued anchors and NDA boundary cleanly.
Buyers, partners, and press should see the same conviction: proof before consequential action.
The HALTSEAL / NOVACOV runtime-control lane is now anchored by two issued U.S. grants on record: US 12,602,481 B1 and US 12,608,476 B1. The public site stays narrow by design; deeper diligence begins under NDA.
Product pages are informational only. No patent license by publication.